Literature DB >> 24287163

Molecular pathogenesis of chronic cholestatic liver disease: impact on novel therapeutic approaches.

Peter Fickert1, Bruno Stieger2.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24287163     DOI： 10.1016/j.mam.2013.11.001

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN： 0098-2997


× No keyword cloud information.
  2 in total

1.  The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway.

Authors:  Dong-ke Yu; Cai-xia Zhang; Shuang-shuang Zhao; Sheng-hua Zhang; Hao Zhang; Shi-ying Cai; Rong-guang Shao; Hong-wei He
Journal:  Acta Pharmacol Sin       Date:  2015-03-16       Impact factor: 6.150

2.  Sortilin 1 Loss-of-Function Protects Against Cholestatic Liver Injury by Attenuating Hepatic Bile Acid Accumulation in Bile Duct Ligated Mice.

Authors:  Jibiao Li; Benjamin L Woolbright; Wen Zhao; Yifeng Wang; David Matye; Bruno Hagenbuch; Hartmut Jaeschke; Tiangang Li
Journal:  Toxicol Sci       Date:  2018-01-01       Impact factor: 4.849
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.